Switch to
More onapp

How to use scorecard? Learn more

Valiant Laboratories Ltd

VALIANTLAB
Health CarePharmaceuticals
SmallcapWith a market cap of ₹640 cr, stock is ranked 1,639
High RiskStock is 3.45x as volatile as Nifty
147.513.27 (-2.17%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Scorecard

Performance

Low

Hasn't fared well - amongst the low performers

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹640 cr, stock is ranked 1,639
High RiskStock is 3.45x as volatile as Nifty

Key MetricsEdit

No LabelNo Label
1,885.09
PB RatioPB Ratio
6.38
Dividend YieldDiv. Yield
Sector PESector PE
45.17
Sector PBSector PB
6.11
Sector Div YldSctr Div Yld
0.56%

Forecast & RatingsDetailed Forecast 

Forecast data is currently unavailable for this stock

Price

Price Upside

Earnings

Earnings Growth

Revenue

Rev. Growth

See Detailed Forecast

Company Profile

Valiant Laboratories Limited specializes in manufacturing pharmaceutical intermediates, particularly paracetamol API.

Financial TrendFinancial statements 

20232024338.77191.7429.000.32
Revenue
Profit
All values in ₹ cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has almost stayed constant

See detailed holdings

Recent NewsAll news 

Hmm, looks like data is unavailable here. Please come back after some time
See all news

Recent EventsAll events 

Trading Window-XBRL 
Announced OnJun 26, 2024

Valiant Laboratories Limited has informed the Exchange about Closure of Trading Window | Download

Valiant Laboratories Limited has informed the Exchange about Closure of Trading Window | Download

Reply to Clarification- Financial results 
Announced OnJun 7, 2024

The Exchange had sought clarification from Valiant Laboratories Limited for the quarter ended 31-Mar-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Segment details not submitted The response of the Company is enclosed. | Download

The Exchange had sought clarification from Valiant Laboratories Limited for the quarter ended 31-Mar-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company was required to clarify the following: -1. Segment details not submitted The response of the Company is enclosed. | Download

Clarification - Financial Results 
Announced OnJun 6, 2024
The Exchange has sought clarification from Valiant Laboratories Limited for the quarter ended 31-Mar-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.
The Exchange has sought clarification from Valiant Laboratories Limited for the quarter ended 31-Mar-2024 with respect to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. On basis of above the Company is required to clarify the following: -1. Segment details not submitted The response of the Company is awaited.
See all events